PolyPeptide draws takeover interest from EQT and KKR
Monday, April 13, 2026 · first reported by Private Equity Wire
EQT and KKR exploring acquisition of Swiss CDMO PolyPeptide Group AG.
- Firm
- EQT
- Also named
- KKR & Co, PolyPeptide Group AG
- Asset class
- Private equity
- Geography
- Europe
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore on EQT
Everything on this firm →- EQT hires UK’s Universities Superannuation Scheme PE head for new rolePrivate Equity International
- EQT agrees to sell Nordic Ferry Infrastructure stake to consortiumPE Hub
- Intertek rejects EQT’s $11bn takeover proposalPrivate Equity Wire
- EQT revives sale of contact lens maker Ginko at $1bn-plus valuationPrivate Equity Wire
More in Deals
From the same day- Sovereign Partners, HudsonPoint Capital to Buy 575 Fifth Avenue for Roughly $385MCommercial Observer
- MKH Capital snaps up Haven Health ManagementPE Hub
- Commvault explores sale amid private equity interestPrivate Equity Wire
- Staple Investments backs Corporate Travel ServicesPE Hub
- Bridgepoint-backed Alpha FMC to acquire JPSBPE Hub
- Eurazeo to acquire Netco from ArdianPE Hub